Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2005

View Archived Issues

RNAse H inhibitor effective against wild-type and NNRTI-resistant HIV-1 strains

Preclinical evidence for improved antineoplasticity using decitabine/zebularine combination therapy

Phase III trials planned for BEMA fentanyl

COLD-fX studied to prevent seniors from influenza in Canadian nursing homes

Avanir acquires additional Neurodex rights

Hematide stimulates production of red blood cells in phase I study

Zealand Pharma and Wyeth expand gap junction modulator collaboration

New phase IV multiple myeloma retreatment study for Velcade

Antitumor effects found for TG-4010 in prostate cancer patients

Update on the safety and immunogenicity of rsPSMA vaccine in prostate cancer

Vitex and Panacos shareholders approve merger

Xoma awarded contract for botulinum neurotoxin monoclonal antibodies

Antisense Therapeutics halts phase IIa study of ATL-1102 for MS

Basilea advances compound with potential for acne and rosacea

Enrollment completed in phase I study of CTCE-0214

First patient enrolled in phase II ThromboView study

RPI-1 effective against medullary thyroid carcinoma in a preclinical model

Role for endogenous opioids in perinatal skeletal development

WNT antagonism via sFRPs: possible therapy for promoting chondrogenesis

mGluR5 antagonist exerts antidepressant effects in rodent models

Novel ACE2 inhibitor identified using structure-based method

New compounds for the treatment of diabetes claimed by Allergan

Orally bioavailable antiestrogen from Chugai for breast cancer treatment

Highly selective AR antagonist presented as a monotherapy candidate for prostate cancer

First data describing MB-06322, an antidiabetic agent in phase II trials

Specific GABAAalpha2/3 agonist shows potential for the treatment of anxiety

Gene therapy for the treatment of cancer reported by Cell Genesys

Patents claiming new agents for the treatment of cancer

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....